| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, February 12, 2018 The math is simple, but managing a company isn’t. That’s the message we gleaned in analyzing productivity at major pharmas and biotech companies. |
|
|
| This week's sponsor is Biotech Primer. | | | |
Top Stories Of The Week Wednesday, February 14, 2018 Bristol-Myers Squibb is paying Nektar Therapeutics $1 billion to develop NKTR-214 in combination with Opdivo and Yervoy. All told, Bristol-Myers is committing $3.6 billion to a deal that gives Nektar the lion’s share of NKTR-214 profits and leaves it some freedom to develop the drug in combination with other assets. Thursday, February 15, 2018 A Celgene spinout known as Celularity with some of the biggest names across biotech and Silicon Valley has raised an eye-watering $250 million for its work in cancer. Friday, February 9, 2018 New court documents filed by lawsuit plaintiffs, including decades-old internal memos, challenge Johnson & Johnson's assertion that its talc products have always been free of asbestos. Wednesday, February 14, 2018 A Merck manufacturing site in Ireland that was slated to close has been saved by the drugmaker’s hot-selling cancer drug Keytruda. Monday, February 12, 2018 Abbott and Johnson & Johnson have told the FDA which medical device regulations they think the agency should scrap or revise. The device makers and 22 other organizations proposed how the FDA can cut the regulatory burden by hundreds of millions of dollars and comply with President Trump’s anti-red tape executive orders. Tuesday, February 13, 2018 GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017, and that was without much contribution from its newly launched shingles vaccine, Shingrix. Thursday, February 8, 2018 Last summer, a research team led by the University of California at San Diego published compelling evidence that a 30-year-old asthma drug called amlexanox could be effective at fighting Type 2 diabetes and obesity. Now they believe they’ve figured out why the drug helps burn calories—and it all ties into inflammation. Monday, February 12, 2018 Eli Lilly says it isn’t afraid of new competition to diabetes drug Trulicity from Novo Nordisk’s Ozempic, known generically as semaglutide. The company is “extremely well prepared for semaglutide’s launch,” diabetes head Enrique Conterno recently told investors. Tuesday, February 13, 2018 Following the recent acquisitions of Brains On-Line and KWS BioTest, Charles River Laboratories is once again mobilizing its M&A war chest, taking in nonclinical contract research organization MPI Research for about $800 million in cash. | This week's sponsor is Iowa Biotechnology Association.. | | | |
Resources Presented by: SDC and Stiris Research What do you do when timelines are missed, data is dirty, and everyone is pointing fingers? Watch this webinar to learn how to prevent, identify, and implement a successful clinical trial rescue. Presented by: Patheon Download Patheon’s whitepaper to discover two main areas where a drug developer can face significant obstacles during biologics development and how by evaluating these capabilities, it can answer the critical question of whether its in-house strategy is ready for these uncertainties. | 